The companies will provide assays for functional comparability, for use in quality control, lot release, and stability testing of biosimilars and biobetters.
SGS, a biopharmaceutical, analytical, and bioanalytical contract solutions provider, entered into a collaboration with DiscoverX, a life-science company that supplies cell-based assays and services for drug discovery and development, according to a March 30, 2016 press announcement. Under the terms of the agreement, SGS and DiscoverX will provide assays for functional comparability, for use in quality control, lot release, and stability testing of biosimilars and biobetters.
According to SGS, DiscoverX has developed bioassays for a number of biologic drugs that are set to lose patent protection over the next 10 years. SGS has initiated the evaluation and qualification of these assays and plans to offer these as a service within a good manufacturing practice or good clinical practice environment.
SGS notes data on the first assay qualification studies will be presented at the CASSS Bioassays 2016 Conference in Silver Spring, MD from April 4-5, 2016. SGS says they will offer the functional comparability assay services to clients under GMP/GCP from its Poitiers, France laboratory.
Source: SGS
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.